Juan F. Zhang

Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Published: July 17, 2023

Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression.

Journal: Cardiovascular drugs and therapy

Published: April 20, 2023

3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension: Results From PADN-5 Trial.

Journal: JACC. Heart failure

Published: February 16, 2023

Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial.

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Published: October 04, 2022

IL-22BP Attenuates Right Ventricular Remodeling in Pulmonary Arterial Hypertension.

IL-22BP Attenuates Right Ventricular Remodeling in Pulmonary Arterial Hypertension.

Aggregatibacter actinomycetemcomitans exacerbates colitis and perturbs the gut microbiota in a murine model​.

Aggregatibacter actinomycetemcomitans exacerbates colitis and perturbs the gut microbiota in a murine model​.

Secretory Carrier Membrane Protein 3 Knockdown Attenuates Hypoxic Pulmonary Hypertension Potentially Involving WW Domain-Containing E3 Ubiquitin Protein Ligase 1.

Secretory Carrier Membrane Protein 3 Knockdown Attenuates Hypoxic Pulmonary Hypertension Potentially Involving WW Domain-Containing E3 Ubiquitin Protein Ligase 1.

Pulmonary artery denervation improves left ventricular diastolic function in patients with isolated post-capillary pulmonary hypertension secondary to heart failure with preserved ejection fraction: a safety and proof-of-principle cohort study.

Pulmonary artery denervation improves left ventricular diastolic function in patients with isolated post-capillary pulmonary hypertension secondary to heart failure with preserved ejection fraction: a safety and proof-of-principle cohort study.

Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker.

Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker.

Pim3 up-regulation by YY1 contributes to diabetes-induced cardiac hypertrophy and heart failure.

Pim3 up-regulation by YY1 contributes to diabetes-induced cardiac hypertrophy and heart failure.

Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer.

Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer.

USP36-mediated PARP1 deubiquitination in doxorubicin-induced cardiomyopathy.

USP36-mediated PARP1 deubiquitination in doxorubicin-induced cardiomyopathy.

A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial.

A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial.

Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression.

Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression.

3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension: Results From PADN-5 Trial.

3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension: Results From PADN-5 Trial.

Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial.

Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial.

Aggregatibacter actinomycetemcomitans exacerbates colitis and perturbs the gut microbiota in a murine model.

Aggregatibacter actinomycetemcomitans exacerbates colitis and perturbs the gut microbiota in a murine model.